PCAT6 May Be a Whistler and Checkpoint Target for Precision Therapy in Human Cancers

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Long non-coding RNAs (lncRNAs) play significant roles in cancer initiation and progression.
• PCAT6, a recently identified carcinogenic lncRNA, is frequently overexpressed in human cancers.
• PCAT6 influences cancer cell behaviors through various mechanisms, including miRNA sponging.

Purpose of the Study:

• To review the biological characteristics of PCAT6 in human malignancies.
• To elucidate the mechanisms by which PCAT6 promotes tumor progression.
• To discuss the diagnostic, prognostic, and clinical potential of PCAT6.

Main Methods:

• Literature review of studies on PCAT6 in cancer.
• Analysis of PCAT6's roles in tumor cell proliferation, migration, invasion, cell cycle, apoptosis, and resistance.
• Evaluation of PCAT6's function beyond competing endogenous RNA (ceRNA) mechanisms.

Main Results:

• PCAT6 is abnormally elevated in numerous human cancers.
• PCAT6 acts as a ceRNA, sponging miRNAs to activate signaling pathways.
• PCAT6 affects critical cancer cell processes including proliferation, migration, invasion, cell cycle, apoptosis, radioresistance, and chemoresistance.
• PCAT6 exhibits functions beyond the ceRNA network.

Conclusions:

• PCAT6 is a key facilitator of tumor progression across various malignancies.
• PCAT6 demonstrates significant potential as a diagnostic and prognostic biomarker.
• Further research into PCAT6's clinical applications in oncology is warranted.